NR3C2 and neoplasm: Although both CCR1i and CCR5i caused a significant decrease in pro-tumour MR+Ly6C- IM numbers at the late stage compared with the control, in the CCR1i treated group this ensured an unchanged frequency of pro-tumour Ly6C- cells within the total IM population from d3 to d21, while in the CCR5i treated group the Ly6C- IM frequency significantly increased from d3 to d21.